Skip to main content

01-09-2016 | Scleroderma | Article

An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: The LOTUSS trial

Khanna D et al. J Rheumatol 216; 43: 1672–1679. doi: 10.3899/jrheum.151322

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

Related topics